Boron / Casp3 Cancer Research Results

Boron — Boron is a trace element; in human systemic biology its dominant freely circulating simple inorganic form is boric acid. In this context it is best classified as a micronutrient/exposure class rather than a single anticancer drug entity, although pharmacologic boric acid, boron-delivery agents for boron neutron capture therapy, and synthetic boron-containing drugs represent distinct therapeutic subcategories. Standard abbreviations include B and BA (boric acid). Natural dietary boron is derived mainly from plant foods, while experimental oncology literature most often studies boric acid or specialized boron carriers. The most defensible cancer relevance is preclinical for oral/systemic boric acid, whereas clinically validated boron use exists mainly in BNCT with borofalan (10B), which is a separate radiation-linked modality rather than ordinary nutritional boron supplementation.

Primary mechanisms (ranked):

1. Calcium-signaling modulation, especially altered intracellular Ca²⁺ release/homeostasis that can impair proliferation and favor growth arrest or apoptosis in some tumor models.
2. Concentration-dependent redox stress with mitochondrial dysfunction and apoptosis at pharmacologic boric-acid exposures.
3. ER-stress / UPR / autophagy coupling (secondary; model-dependent), contributing to cytostasis or cell death in some recent cell-line studies.
4. Suppression of selected pro-survival and inflammatory signaling axes such as NF-κB, ERK, and related metastatic programs (context-dependent; less consistently established than Ca²⁺ and redox effects).
5. Weak epigenetic enzyme interaction, including HDAC-related effects, mechanistically plausible but not yet a core translational driver for simple boric acid.
6. For boron-delivery oncology platforms, neutron-capture radiosensitization is the clinically validated mechanism, but this applies to BNCT carriers such as borofalan (10B), not to routine dietary boron supplementation.

Bioavailability / PK relevance: Oral boric acid is very well absorbed, not metabolized, distributes largely with body water, and is cleared predominantly in urine; systemic boron exposure is therefore achievable, but renal function is a key determinant of safety. Bone can retain boron longer than soft tissues. For ordinary supplements, exposure is limited by tolerability and reproductive/developmental safety ceilings rather than by poor absorption.

In-vitro vs systemic exposure relevance: Common mechanistic cell-culture studies often use ~0.1–1 mM for signaling effects and several mM for stronger oxidative/apoptotic effects; normal human plasma boron is usually only ~10–20 µM. Thus, many direct anticancer in-vitro effects likely require exposures above usual nutritional/systemic levels achievable with standard oral supplementation. BNCT is different because efficacy depends on selective tumor boron delivery plus neutron irradiation, not on free systemic boron concentration alone.

Clinical evidence status: Oral/systemic boron or boric acid as an anticancer agent remains preclinical, with observational nutrition data only and no established cancer-treatment trials supporting routine use. In contrast, boron neutron capture therapy is a clinically deployed adjunct/local treatment platform in Japan for selected unresectable locally advanced or locally recurrent head and neck cancers when delivered with borofalan (10B) and dedicated neutron-irradiation systems.

Mechanistic matrix: Boron Pathways for Cancer vs Normal cells

P: 0–30 min

R: 30 min–3 hr

G: >3 hr

Distinct from compounds of main Redox Driver
| Compound            | ROS ↑ mechanism             | Category            |
| ------------------- | --------------------------- | ------------------- |
| PEITC               | Direct electrophilic stress | Redox driver        |
| Selenium (selenite) | Redox cycling               | Redox driver        |
| Thymoquinone        | Quinone cycling             | Redox driver        |
| **Boron**           | Metabolic redox imbalance   | **Secondary redox** |